This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dring, A. M. Articles by Morgan, G. J. Search for Related Content PubMed PubMed Citation Articles by Dring, A. M. Articles by Morgan, G. J.

A Global Expression-based Analysis of the Consequences of the t(4;14) Translocation in Myeloma

¹ Academic Unit of Haematology and Oncology, University of Leeds, Leeds, United Kingdom; ² Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts; ³ Jerome Lipper Multiple Myeloma Center; Dana-Farber Cancer Institute, Boston, Massachusetts; and ⁴ Royal Marsden Hospital, Surrey, United Kingdom

ABSTRACT

Purpose: Our purpose in this report was to define genes and pathways dysregulated as a consequence of the t(4;14) in myeloma, and to gain insight into the downstream functional effects that may explain the different prognosis of this subgroup.

Experimental Design: Fibroblast growth factor receptor 3 (FGFR3) overexpression, the presence of immunoglobulin heavy chain-multiple myeloma SET domain (IgH-MMSET) fusion products and the identification of t(4;14) breakpoints were determined in a series of myeloma cases. Differentially expressed genes were identified between cases with (n = 5) and without (n = 24) a t(4;14) by using global gene expression analysis.

Results: Cases with a t(4;14) have a distinct expression pattern compared with other cases of myeloma. A total of 127 genes were identified as being differentially expressed including MMSET and cyclin D2, which have been previously reported as being associated with this translocation. Other important functional classes of genes include cell signaling, apoptosis and related genes, oncogenes, chromatin structure, and DNA repair genes. Interestingly, 25% of myeloma cases lacking evidence of this translocation had up-regulation of the MMSET transcript to the same level as cases with a translocation.

Conclusions: t(4;14) cases form a distinct subgroup of myeloma cases with a unique gene signature that may account for their poor prognosis. A number of non-t(4;14) cases also express MMSET consistent with this gene playing a role in myeloma pathogenesis.

This article has been cited by other articles:

				J. Marango, M. Shimoyama, H. Nishio, J. A. Meyer, D.-J. Min, A. Sirulnik, Y. Martinez-Martinez, M. Chesi, P. L. Bergsagel, M.-M. Zhou, et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor Blood, March 15, 2008; 111(6): 3145 - 3154. [Abstract] [Full Text] [PDF]

				J. Lauring, A. M. Abukhdeir, H. Konishi, J. P. Garay, J. P. Gustin, Q. Wang, R. J. Arceci, W. Matsui, and B. H. Park The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity Blood, January 15, 2008; 111(2): 856 - 864. [Abstract] [Full Text] [PDF]

				K. Podar, M. S. Raab, J. Zhang, D. McMillin, I. Breitkreutz, Y.-T. Tai, B. K. Lin, N. Munshi, T. Hideshima, D. Chauhan, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl) Blood, February 15, 2007; 109(4): 1669 - 1677. [Abstract] [Full Text] [PDF]

				E. Masih-Khan, S. Trudel, C. Heise, Z. Li, J. Paterson, V. Nadeem, E. Wei, D. Roodman, J. O. Claudio, P. L. Bergsagel, et al. MIP-1{alpha} (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma Blood, November 15, 2006; 108(10): 3465 - 3471. [Abstract] [Full Text] [PDF]

				T. Hideshima, D. Chauhan, P. Richardson, and K. C. Anderson Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma J. Clin. Oncol., September 10, 2005; 23(26): 6345 - 6350. [Abstract] [Full Text] [PDF]

				H. Chang, A. K. Stewart, X. Y. Qi, Z. H. Li, Q. L. Yi, and S. Trudel Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma Blood, July 1, 2005; 106(1): 353 - 355. [Abstract] [Full Text] [PDF]

				J. J. Keats, C. A. Maxwell, B. J. Taylor, M. J. Hendzel, M. Chesi, P. L. Bergsagel, L. M. Larratt, M. J. Mant, T. Reiman, A. R. Belch, et al. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients Blood, May 15, 2005; 105(10): 4060 - 4069. [Abstract] [Full Text] [PDF]